MTVA
MetaVia Inc.

14,782
Mkt Cap
$4.67M
Volume
121,460.00
52W High
$23.10
52W Low
$1.34
PE Ratio
-0.09
MTVA Fundamentals
Price
$1.41
Prev Close
$1.48
Open
$1.49
50D MA
$2.47
Beta
0.96
Avg. Volume
339,391.83
EPS (Annual)
-$39.13
P/B
0.49
Rev/Employee
$0.00
$0.134
Loading...
Loading...
News
all
press releases
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and...
PR Newswire·4d ago
News Placeholder
More News
News Placeholder
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and...
PR Newswire·10d ago
News Placeholder
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences...
PR Newswire·18d ago
News Placeholder
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR...
PR Newswire·1mo ago
News Placeholder
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 MetaVia Builds Comprehensive Global Patent Protection...
PR Newswire·1mo ago
News Placeholder
What Does the Market Think About MetaVia Inc?
read more...
Benzinga·2mo ago
News Placeholder
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering...
PR Newswire·2mo ago
News Placeholder
MetaVia Stock Slides After Pricing Public Offering
(RTTNews) - MetaVia Inc. (MTVA) shares traded at $3.4050, down 39.03% or $2.18 lower, after the company announced the pricing of an $8.1 million underwritten public offering...
Nasdaq News: Markets·2mo ago
News Placeholder
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering PR Newswire CAMBRIDGE, Mass., Jan. 15, 2026...
PR Newswire·2mo ago
News Placeholder
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic...
PR Newswire·3mo ago
<
1
2
...
>

Latest MTVA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.